ENJAYMO—THE FIRST AND ONLY APPROVED TREATMENT FOR CAD1
ENJAYMO is a classical complement inhibitor indicated to decrease the need for red blood cell transfusion due to hemolysis in adults with Cold Agglutinin Disease (CAD).
JOIN US AT THE ASH ANNUAL MEETING FOR A PRESENTATION ON ENJAYMO | MONDAY 12/12 @ 8 am
VISIT US AT ASH | DECEMBER 10-13 | BOOTH #643
ENJAYMO is a classical complement inhibitor indicated to decrease the need for red blood cell transfusion due to hemolysis in adults with Cold Agglutinin Disease (CAD).
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.
Serious Infections
Infusion-Related Reactions
Risk of Autoimmune Disease
Recurrent Hemolysis After ENJAYMO Discontinuation
ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Please see full Prescribing Information.
See the full Medication Guide.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.
Serious Infections
Infusion-Related Reactions
Risk of Autoimmune Disease
Recurrent Hemolysis After ENJAYMO Discontinuation
ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Please see full Prescribing Information.
See the full Medication Guide.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.